Movement Alert｜Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress

Market Focus

Jul 02

On July 2, Innovent Biologics rose 4.27% in regular trading, trading at 82.9 HKD/share, with turnover of 322 million HKD. Multiple positive catalysts converged to drive the stock higher.

On June 30, Innovent Biologics signed a commercialization agreement with Eli Lilly for Verzenios (abemaciclib), a CDK4/6 inhibitor, in mainland China. Under the agreement, Innovent holds exclusive rights to import, market, distribute, and promote the drug domestically, strengthening its breast cancer pipeline. Eli Lilly retains responsibility for manufacturing, supply, and ongoing R&D.

Additionally, the company's core product mazdutide passed the preliminary review for inclusion in China's national medical insurance drug catalog on June 29, marking a critical step toward reimbursement coverage. A company spokesperson noted that only the diabetes indication is eligible for insurance consideration in China.

Within the Biotechnology sector, stocks broadly rallied. Among individual names, 3SBIO rose 11.66%, Akeso rose 8.4%, Remegen rose 6.86%, SKB Bio rose 5.59%, and BeiGene rose 2.05%, reflecting strong sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1187885412"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187885412\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187885412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187885412","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress","media":"Market Focus","content":"<p><p>On July 2, Innovent Biologics rose 4.27% in regular trading, trading at 82.9 HKD/share, with turnover of 322 million HKD. Multiple positive catalysts converged to drive the stock higher.</p><p>On June 30, Innovent Biologics signed a commercialization agreement with Eli Lilly for Verzenios (abemaciclib), a CDK4/6 inhibitor, in mainland China. Under the agreement, Innovent holds exclusive rights to import, market, distribute, and promote the drug domestically, strengthening its breast cancer pipeline. Eli Lilly retains responsibility for manufacturing, supply, and ongoing R&D.</p><p>Additionally, the company's core product mazdutide passed the preliminary review for inclusion in China's national medical insurance drug catalog on June 29, marking a critical step toward reimbursement coverage. A company spokesperson noted that only the diabetes indication is eligible for insurance consideration in China.</p><p>Within the Biotechnology sector, stocks broadly rallied. Among individual names, 3SBIO rose 11.66%, Akeso rose 8.4%, Remegen rose 6.86%, SKB Bio rose 5.59%, and BeiGene rose 2.05%, reflecting strong sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Innovent Biologics rose 4.27% in regular trading, trading at 82.9 HKD/share, with turnover of 322 million HKD. Multiple positive catalysts converged to drive the stock higher.</p><p>On June 30, Innovent Biologics signed a commercialization agreement with Eli Lilly for Verzenios (abemaciclib), a CDK4/6 inhibitor, in mainland China. Under the agreement, Innovent holds exclusive rights to import, market, distribute, and promote the drug domestically, strengthening its breast cancer pipeline. Eli Lilly retains responsibility for manufacturing, supply, and ongoing R&D.</p><p>Additionally, the company's core product mazdutide passed the preliminary review for inclusion in China's national medical insurance drug catalog on June 29, marking a critical step toward reimbursement coverage. A company spokesperson noted that only the diabetes indication is eligible for insurance consideration in China.</p><p>Within the Biotechnology sector, stocks broadly rallied. Among individual names, 3SBIO rose 11.66%, Akeso rose 8.4%, Remegen rose 6.86%, SKB Bio rose 5.59%, and BeiGene rose 2.05%, reflecting strong sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1187885412","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187885412","pubTimestamp":1782955911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Innovent Biologics rose 4.27% in regular trading, trading at 82.9 HKD/share, with turnover of 322 million HKD. Multiple positive catalysts converged to drive the stock higher.On June 30,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动静快讯|信达生物常规交易涨4.27%礼来商业化交易及Mazdutide保险审查进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On July 2, Innovent Biologics rose 4.27% in regular trading, trading at 82.9 HKD/share, with turnover of 322 million HKD. Multiple positive catalysts converged to drive the stock higher.On June 30, Innovent Biologics signed a commercialization agreement with Eli Lilly for Verzenios (abemaciclib), a CDK4/6 inhibitor, in mainland China. Under the agreement, Innovent holds exclusive rights to import, market, distribute, and promote the drug domestically, strengthening its breast cancer pipeline. Eli Lilly retains responsibility for manufacturing, supply, and ongoing R&D.Additionally, the company's core product mazdutide passed the preliminary review for inclusion in China's national medical insurance drug catalog on June 29, marking a critical step toward reimbursement coverage. A company spokesperson noted that only the diabetes indication is eligible for insurance consideration in China.Within the Biotechnology sector, stocks broadly rallied. Among individual names, 3SBIO rose 11.66%, Akeso rose 8.4%, Remegen rose 6.86%, SKB Bio rose 5.59%, and BeiGene rose 2.05%, reflecting strong sector-wide momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}